RT Journal Article
SR Electronic
T1 Short-Term Immune Response After Inactivated SARS-CoV-2 (CoronaVac®, Sinovac) And ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) Vaccinations in Thai Health Care Workers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.27.21262721
DO 10.1101/2021.08.27.21262721
A1 Watsamon Jantarabenjakul
A1 Napaporn Chantasrisawad
A1 Thanyawee Puthanakit
A1 Supaporn Wacharapluesadee
A1 Nattiya Hirankarn
A1 Vichaya Ruenjaiman
A1 Leilani Paitoonpong
A1 Gompol Suwanpimolkul
A1 Pattama Torvorapanit
A1 Rakchanok Pradit
A1 Jiratchaya Sophonphan
A1 Opass Putcharoen
YR 2021
UL http://medrxiv.org/content/early/2021/08/30/2021.08.27.21262721.abstract
AB Background Inactivated SARS-CoV-2 (CoronaVac®,Sinovac, or SV) and ChAdOx1 nCoV-19 (Vaxzevria®,Oxford-Astra Zeneca, or AZ) vaccines have been administered to the health care workers (HCWs) in Thailand.Objective To determine the short-term immune response after the SV and AZ vaccinations in HCWs.Methods In this prospective cohort study, HCWs who completed a 2-dose regimen of the SV or AZ were included. Immune response was evaluated by surrogate viral neutralization test (sVNT) and anti-SARS-CoV-2 total antibody. Blood samples were analyzed at 4 and 12 weeks after the complete SV vaccination and at 4 weeks after each dose of the AZ vaccination. The primary outcome was the seroconversion rate at 4-weeks after complete immunization.Results Overall, 185 HCWs with a median (IQR) age of 40.5(30.3-55.8) years (94 HCWs in the SV group and 91 in the AZ group) were included. At 4 weeks after completing the SV vaccination, 60.6% (95%CI:50.0-70.6%) had seroconversion evaluated by sVNT(≥68%inhibition), comparable to the patients recovered from mild COVID-19 infection(69.0%), with a rapid reduction to 12.2%(95%CI:6.3-20.8) at 12 weeks. In contrast, 85.7%(95%CI:76.8-92.2%) HCWs who completed the second dose of the AZ for 4 weeks had seroconversion, comparable to the COVID-19 pneumonia patients(92.5%). When using the anti-SAR-CoV-2 total antibody level(≥132 U/ml) criteria, only 71.3% HCWs in the SV group had seroconversion, compared to 100% in the AZ group.Conclusion A rapid decline of short-term immune response in the HCWs after the SV vaccination indicates the need for a vaccine booster, particularly during the ongoing spreading of the SAR-CoV-2 variants of concern.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialTCTR20210325003Funding StatementThe Rachadaphiseksomphot Fund (RA(PO)002/64) from the Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital Fund for research (HA-64-3300-21-024). NH was supported by the Ratchadaphiseksomphot Matching Fund from the Faculty of Medicine, Chulalongkorn University. VR was supported by the Postdoctoral Fellowship Scholarships, Ratchadapisek Somphot Fund, Chulalongkorn University. Part of this work was supported by the Biobank, Faculty of Medicine, Chulalongkorn University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Research Ethics Review Committee, Faculty of Medicine, Chulalongkorn University, and was registered to the Thai Clinical Trial (TCTR20210325003).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, [OP]. The data are not publicly available due to their containing information that could compromise the privacy of research participants.